(Yicai Global) Jan. 21 -- Although it is located in Daxing, a high-risk area of Beijing, Sinovac Biotech revealed today that its current daily output of more than 400,000 doses of Covid-19 vaccines has been unaffected, Beijing Daily reported.

"We’re only one kilometer away from Ronghui, a high-risk area, but our production has not been affected," said Lian Xiaojuan, head of production at Sinovac Research & Development.

The tightening of epidemic prevention and control measures following the recent outbreak could have hit the transportation of materials, but the biomedical industry base where Sinovac R&D is located applied for a green channel for the company, Lian added.

The company also said that more than 1,100 builders are working on its phase II and phase III production workshops and mass production is expected to begin at the phase II workshop next month.

Sinovac Biotech said last month it had received investment of USD515 million from Sino Biopharmaceutical, which will be used for development, capacity expansion and production of Covid-19 inactivated vaccines. The company also said it plans to build a coronavirus vaccine production base with an annual capacity of 150 million doses by the end of 2021.

Its inactivated Covid-19 vaccines have obtained emergency use authorization from countries including Brazil, Chile and Indonesia.

Editor: Tom Litting